A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections.

Machine translation Machine translation
作者 Zachariah J -More
类别 Primary study
期刊The Journal of antimicrobial chemotherapy
Year 1996
連結 Pubmed, DOI
在大型，双盲对比研究，评估的临床和细菌学疗效和耐受性的阿奇霉素（500毫克，每天一次，连续3天）和拉维酸（37毫克，每日三次）为期10天的养生之道急性下呼吸道感染369例（>或= 18岁）。治疗后，165/173（95％），阿奇霉素和166/173（96％），拉维酸治疗的患者令人满意的回应（治愈或改善）。在82/82（100％），阿奇霉素和73/74（99％），拉维酸治疗的病人的细菌含量应课税基线病原体（主要是肺炎链球菌和流感嗜血杆菌）被根除。13/186（7％），阿奇霉素和19/183（10％），拉维酸治疗的患者不良事件，主要为轻度至中度，主要影响胃肠道系统，记录。只有两个人（1％），阿奇霉素治疗的病人停止治疗，由于不良事件相比，8个（4％）联合amoxiclav。结果表明，阿奇霉素的剂量为500毫克，每日一次，连续3天到10天，每天三次的下呼吸道感染的成人患者在治疗的过程中，拉维酸是一种有效和安全的替代。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: 686e11361f773ad3544a48329d62ff3cfc925dbf
First added on: Oct 12, 2012
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use